MedPath

Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer

Not Applicable
Not yet recruiting
Conditions
Lung Cancer
Registration Number
NCT05799027
Lead Sponsor
China-Japan Friendship Hospital
Brief Summary

The goal of this clinical trial is to evaluate raman spectroscopic analysis of bronchoscopic biopsy for diagnosing lung cancer in visible lesions in the airway. The main question it aims to answer are: the diagnostic efficacy raman spectroscopic analysis of bronchoscopic biopsy for diagnosing lung cancer.

The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Patients who plan to undergo bronchoscopic biopsy or EBUS-TBNA
  • Visible intratracheal lesions under bronchoscope
  • Non-visible lesions suspected of lung cancer
Exclusion Criteria
  • The patient could not tolerate further examination aimed at clarifying the cause of the disease or refused to accept further examination aimed at clarifying the cause of the disease due to poor general condition, serious organ dysfunction, etc
  • The patient has no definite diagnosis

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
To establish the sensitivities and specificities of Raman spectroscopic analysis of bronchoscopic biopsy for lung cancer.7 days after the biopsy

The diagnosis would be confirmed according to the pathological results.

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.